The efficacy of oromucosal immunotherapy in respiratory allergy

[1] Safety of sublingual-swallow immunotherapy in children and adults [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2000, 121 (03) : 229 - 234

[2] Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 100 (01) : 122 - 129

[3] Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (01) : 54 - 60

[4] EVALUATION OF IMMUNOTHERAPY-INDUCED CHANGES IN SPECIFIC IGE, IGG AND IGG SUBCLASSES IN BIRCH POLLEN ALLERGIC PATIENTS BY MEANS OF IMMUNOBLOTTING - CORRELATION WITH CLINICAL-RESPONSE [J]. ALLERGY, 1990, 45 (06) : 418 - 426

[5] Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites:: a double-blind, placebo-controlled study [J]. ALLERGY, 1999, 54 (03) : 249 - 260

[6] Bousquet J., 1998, Allergy (Copenhagen), V53, P1

[7] CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305

[8] Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis [J]. ALLERGY, 1998, 53 (05) : 493 - 498

[9] Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 1997, 27 (09) : 1007 - 1015

[10] Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1999, 120 (03) : 218 - 224

[1] Safety of sublingual-swallow immunotherapy in children and adults [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2000, 121 (03) : 229 - 234

[2] Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 100 (01) : 122 - 129

[3] Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (01) : 54 - 60

[4] EVALUATION OF IMMUNOTHERAPY-INDUCED CHANGES IN SPECIFIC IGE, IGG AND IGG SUBCLASSES IN BIRCH POLLEN ALLERGIC PATIENTS BY MEANS OF IMMUNOBLOTTING - CORRELATION WITH CLINICAL-RESPONSE [J]. ALLERGY, 1990, 45 (06) : 418 - 426

[5] Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites:: a double-blind, placebo-controlled study [J]. ALLERGY, 1999, 54 (03) : 249 - 260

[6] Bousquet J., 1998, Allergy (Copenhagen), V53, P1

[7] CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305

[8] Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis [J]. ALLERGY, 1998, 53 (05) : 493 - 498

[9] Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 1997, 27 (09) : 1007 - 1015

[10] Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1999, 120 (03) : 218 - 224